ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2026
A network pharmacology-based strategy to discover the molecular mechanism of correlation between the treatment of bronchial asthma with Wenyang Huayin decoction and autophagy.
Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo investigate the key targets and mechanisms of the Wenyang Huayin decoction (WYHYD, ) in treating bronchial asthma with cold fluid retention syndrome using network pharmacology and animal experiments.
methodsOn the one hand, we used network pharmacology method to explored the chemical components of the WYHYD and the main targets of bronchial asthma were acquired. Besides, a protein interaction network was built after protein interaction analysis to find potential protein functional modules. Then, we constructed the "WYHYD component-bronchial asthma target-pathway" network. On the other hand, the experimental intervention was as follows: first, we formed a rat model of bronchial asthma. Thereafter, we used the WYHYD to treat the disease while observing autophagy-related indicators as the core target of network pharmacology.
resultsThe network pharmacology revealed that there are 122 potential therapeutic targets in treating bronchial asthma with WYHYD. The biological processes mainly involved in the WYHYD included Gene Ontology: 0110032: positive regulation of G2/MI transition of the medical cell cycle etc. and four major signaling pathways were involved. During laboratory investigations, various signs and clinical manifestations of the rat model group were the same. After administering the WYHYD, lung function, pathological sections, inflammatory factors, and other microscopic indicators improved to varying degrees, providing evidence for the study results. Meanwhile, we verified that the core targets of WYHYD in treating asthma through the intervention of autophagy are tumor necrosis factor, caspase 8, interleukin 1 beta, sirtuin 1, phosphatidylinositol 3-kinase catalytic subunit type 3, C-C chemokine receptor type 7, L/YN kinase, and protein tyrosine kinase 2.
conclusionThis preliminary study revealed the treatment process of bronchial asthma with multi-component, multi-target, and multi-pathway mechanisms of the WYHYD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.